Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 388 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Decreased Immunologic Activity Clear all
Completed No phase listed Observational

Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants

NCT00246844
View directory record Official record
Conditions
Long-Functioning Pancreas Allografts, Pancreas Transplant
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

NCT01820572
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept, Tacrolimus, Cyclosporine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 9, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers

NCT01281995
View directory record Official record
Conditions
Immunosuppression, Healthy, Healthy Subjects
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Short Term Effects of Oceanix Supplementation on Recovery

NCT04315077
View directory record Official record
Conditions
Oxidative Stress, Muscle Strength, Resistance Training, Muscle Damage, Immune Suppression
Interventions
Oceanix®, Resistance Training
Dietary Supplement · Other
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

NCT00264251
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Obesity
Interventions
Weight loss through diet and exercise, Rosiglitazone insulin sensitizing agent
Behavioral · Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2007 · Synced Sep 9, 2026, 11:37 PM EDT
Recruiting Phase 1 Interventional

IS-free Treg HaploHCT

NCT04678401
View directory record Official record
Conditions
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions
Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan
Radiation · Drug · Biological + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Islet Transplantation for Patients With Type 1 Diabetes

NCT00073281
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 9, 2026, 11:37 PM EDT
Withdrawn Not applicable Interventional

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

NCT01612299
View directory record Official record
Conditions
Renal Transplant
Interventions
Zortress® /Everolimus
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients

NCT00282243
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus modified release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00133809
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Transplantation of Human Islets
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00658359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
37
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed No phase listed Observational

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

NCT02711709
View directory record Official record
Conditions
Sepsis
Interventions
Frailty Measurements, Modified Minnesota Leisure Time Activities, Computed tomography morphometrics, Mobility Monitors
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

NCT00374049
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC_1
Drug
Lead sponsor
Olivera Finn
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hodgkin Lymphoma, Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants

NCT00018785
View directory record Official record
Conditions
Kidney Disease
Interventions
donor bone marrow infusion
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 9, 2026, 11:37 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications

NCT01633229
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Bone Marrow Stromal Cell Infusion
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation

NCT02736227
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus Withdrawal and Everolimus Monotherapy
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023
View directory record Official record
Conditions
Sepsis
Interventions
Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
Device · Procedure · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 9, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Sep 9, 2026, 11:37 PM EDT
Completed No phase listed Observational

Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols

NCT00839709
View directory record Official record
Conditions
Liver Disease, Liver Transplantation
Interventions
blood sampling
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Sep 9, 2026, 11:37 PM EDT